•
Mar 31, 2023

The Joint Q1 2023 Earnings Report

Reported financial results for the first quarter of 2023.

Key Takeaways

The Joint Corp. reported a 27% increase in revenue and a net income of $2.3 million for Q1 2023, driven by a greater number of clinics and organic growth.

Revenue increased by 27% compared to Q1 2022, reaching $28.5 million.

Net income was $2.3 million, or $0.15 per diluted share, compared to a net loss of $206,000 in Q1 2022.

The company increased its clinic count to 870, including 130 company-owned or managed clinics.

Adjusted EBITDA increased to $2.0 million, compared to $1.8 million in Q1 2022.

Total Revenue
$28.5M
Previous year: $22.4M
+26.8%
EPS
$0.15
Previous year: -$0.01
-1600.0%
System-wide Sales Growth
17%
Gross Profit
$25.8M
Cash and Equivalents
$14.8M
Previous year: $18.3M
-19.1%
Free Cash Flow
$4.82M
Total Assets
$99.6M

The Joint

The Joint

Forward Guidance

Management reiterated financial and clinic opening guidance for 2023, focusing on greenfield clinic openings for company-owned or managed locations.